Race & Breast Cancer Estrogen Receptor Status: Impact of Class and Missing Data
Race & Breast Cancer Estrogen Receptor Status: Impact of Class and Missing Data
批准号:
7289303
负责人:
NANCY KRIEGER
金额:
$7.96万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-21 至 2009-08-31
关键词:
AddressAgeAreaAsiansBiological MarkersBreast Cancer TreatmentCaliforniaCancer CenterCancer PrognosisCensusesCharacteristicsClassColorConsensusCountyDataData SetDatabasesDiagnosisDiagnostic Neoplasm StagingEpidemiologic StudiesEstrogen Receptor StatusEstrogen Receptor Status UnknownEstrogen ReceptorsEstrogen receptor negativeEstrogen receptor positiveEthnic OriginEthnic groupExposure toGene ExpressionHealthy People 2010HispanicsHormone replacement therapyIncidenceInvasiveKnowledgeLinkLiteratureLos AngelesMalignant NeoplasmsMeasuresMedical SurveillanceNational Cancer InstituteNot Hispanic or LatinoPacific Island AmericansPatternPeer ReviewPopulationPositioning AttributeProbabilityPublicationsRaceRangeRateReceptor GeneRecordsResearchRisk FactorsSan FranciscoSurveillance ProgramTechniquesTestingTumor stageUnited States National Institutes of HealthWomanbasecohorthealth disparitymalignant breast neoplasmneoplasm registryoutcome forecastprogramsracial and ethnicracial and ethnic disparitiessizesocioeconomicstumortumor initiation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Despite an apparent scientific consensus that US racial/ethnic groups have disparate distributions of breast cancer estrogen receptor (ER) status, previous studies of this topic are limited by: (1) the sizable proportion of cases with unknown ER status (typically 15-40%). (2) the paucity of socioeconomic data. limiting ability to control for confounding by socioeconomic position, and (3) the near exclusive focus on black/white differences. Suggesting, however, that estimates of racial/ethnic disparities in ER status based on such data might be biased, evidence indicates: (a) ER status is more frequently missing among women of color and/or less affluent women, and (b) risk factors for ER status may themselves be socially patterned, e.g., exposure to hormone replacement therapy, for the last 40 years more common among white and more affluent women, may increase likelihood of developing an ER-positive tumor. Because ER status is a key tumor biomarker relevant to both breast cancer treatment and survival, it is important to gauge accurately the extent to which estimates of racial/ethnic disparities in ER status are real or biased. Accordingly, to assess whether estimates of racial/ethnic disparities in breast cancer ER status and incidence of breast cancer by ER status are biased by missing data on ER status and lack of control for socioeconomic position, we will employ multivariate and sensitivity analysis techniques to analyze a multi- racial/ethnic population-based data set consisting of all incident cases of invasive primary breast cancer among women (n = 42,240 including 26,491 white non-Hispanic; 4,102 black; 4,961 Hispanic, and 4,970 Asian and Pacific Islander cases) occurring between 1998 and 2002 and included in the records of two US population-based cancer registries: the Los Angeles Cancer Surveillance Program and the Northern California Cancer Center. Records include data on race/ethnicity, age at diagnosis, and tumor characteristics and are linked to 2000 census tract socioeconomic data. Analyses will: (1) assess the distribution of ER status (positive, negative, or missing) by race/ethnicity, socioeconomic position, age at diagnosis, and tumor size and tumor stage, to estimate probabilities for the distribution of ER status among those within unknown status; and (2) using multivariate and sensitivity analysis, assess whether missing ER data and lack of control for socioeconomic position bias estimates of racial/ethnic disparities in breast cancer ER status and breast cancer incidence by ER status. Results will provide the first evidence whether estimates of racial/ethnic disparities in ER status are biased due to missing data on ER status and lack of inclusion of socioeconomic data, and will do so in a large multi-racial/ethnic cohort. Findings will provide knowledge needed to address health disparities, a key objective of the National Cancer Institute, the National Institutes of Health, and Healthy People 2010, while also addressing the objectives of PAR- 04-159, by using "existing data" to determine "applicability of biomarkers of tumor initiation and progression for epidemiologic studies."
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Advancing novel methods to measure and analyze multiple types of discrimination for population health research
-
批准号:10330589
-
项目类别:
-
资助金额:$65.13万
-
财政年份:2019
-
负责人:NANCY KRIEGER
-
依托单位:
Advancing novel methods to measure and analyze multiple types of discrimination for population health research
-
批准号:10551734
-
项目类别:
-
资助金额:$64.84万
-
财政年份:2019
-
负责人:NANCY KRIEGER
-
依托单位:
DNA methylation & adversity: pathways from exposures to health inequities
-
批准号:9811618
-
项目类别:
-
资助金额:$63.81万
-
财政年份:2019
-
负责人:NANCY KRIEGER
-
依托单位:
DNA methylation & adversity: pathways from exposures to health inequities
-
批准号:10363700
-
项目类别:
-
资助金额:$56.72万
-
财政年份:2019
-
负责人:NANCY KRIEGER
-
依托单位:
Long-term trends in breast cancer DNA copy number alterations & disparities
-
批准号:9271922
-
项目类别:
-
资助金额:$8.53万
-
财政年份:2016
-
负责人:NANCY KRIEGER
-
依托单位:
Long-Term Trends in Breast Cancer Tumor Profiles & Disparities
-
批准号:8636410
-
项目类别:
-
资助金额:$17.29万
-
财政年份:2013
-
负责人:NANCY KRIEGER
-
依托单位:
Long-Term Trends in Breast Cancer Tumor Profiles & Disparities
-
批准号:8460731
-
项目类别:
-
资助金额:$24.31万
-
财政年份:2013
-
负责人:NANCY KRIEGER
-
依托单位:
Jim Crow & health disparities: exploring age-period-cohort effects
-
批准号:8537876
-
项目类别:
-
资助金额:$27.29万
-
财政年份:2012
-
负责人:NANCY KRIEGER
-
依托单位:
Jim Crow & health disparities: exploring age-period-cohort effects
-
批准号:8325806
-
项目类别:
-
资助金额:$17.73万
-
财政年份:2012
-
负责人:NANCY KRIEGER
-
依托单位:
EXPLORING TRENDS IN US HEALTH INEQUITIES IN CONTEXT: NHES TO NHANES, 1959-2006
-
批准号:8529880
-
项目类别:
-
资助金额:$12.08万
-
财政年份:2011
-
负责人:NANCY KRIEGER
-
依托单位:
EXPLORING TRENDS IN US HEALTH INEQUITIES IN CONTEXT: NHES TO NHANES, 1959-2006
-
批准号:8043418
-
项目类别:
-
资助金额:$24.23万
-
财政年份:2011
-
负责人:NANCY KRIEGER
-
依托单位:
EXPLORING TRENDS IN US HEALTH INEQUITIES IN CONTEXT: NHES TO NHANES, 1959-2006
-
批准号:8212273
-
项目类别:
-
资助金额:$20.19万
-
财政年份:2011
-
负责人:NANCY KRIEGER
-
依托单位:
CANCER AND CHANGING TRENDS IN US MORTALITY INEQUITIES: 1960-2004
-
批准号:7708404
-
项目类别:
-
资助金额:$8.18万
-
财政年份:2009
-
负责人:NANCY KRIEGER
-
依托单位:
CANCER AND CHANGING TRENDS IN US MORTALITY INEQUITIES: 1960-2004
-
批准号:7878045
-
项目类别:
-
资助金额:$8.18万
-
财政年份:2009
-
负责人:NANCY KRIEGER
-
依托单位:
Racial Discrimination and Risk of Chronic Disease
-
批准号:7934415
-
项目类别:
-
资助金额:$11.99万
-
财政年份:2009
-
负责人:NANCY KRIEGER
-
依托单位:
Racial Discrimination and Risk of Chronic Disease
-
批准号:7492137
-
项目类别:
-
资助金额:$63.82万
-
财政年份:2007
-
负责人:NANCY KRIEGER
-
依托单位:
Racial Discrimination and Risk of Chronic Disease
-
批准号:7877776
-
项目类别:
-
资助金额:$62.2万
-
财政年份:2007
-
负责人:NANCY KRIEGER
-
依托单位:
Breast Cancer After The Women?s Health Initiative Study: Declining Incidence?
-
批准号:7384572
-
项目类别:
-
资助金额:$8.15万
-
财政年份:2007
-
负责人:NANCY KRIEGER
-
依托单位:
Racial Discrimination and Risk of Chronic Disease
-
批准号:7313142
-
项目类别:
-
资助金额:$68.59万
-
财政年份:2007
-
负责人:NANCY KRIEGER
-
依托单位:
Breast Cancer After The Women?s Health Initiative Study: Declining Incidence?
-
批准号:7500731
-
项目类别:
-
资助金额:$8.15万
-
财政年份:2007
-
负责人:NANCY KRIEGER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: